Skip to main content

Bradbury Daniel's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Dec 5, 2023

Accession no.
0001447362-23-000163
Filed
Dec 5, 2023
Trade date
Dec 1-4, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions. Open-market sales total $278.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bradbury DanielCIK 0001236397Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2023Common StockSSaleDisposed−3,025$20.06F2−$60,681.576,456Indirect
Dec 1, 2023Common StockSSaleDisposed−3,259$20.06F2−$65,375.5454,502Indirect
Dec 1, 2023Common StockSSaleDisposed−3,261$20.06F2−$65,415.6654,525Indirect
Dec 4, 2023Common StockSSaleDisposed−1,375$20.08F6−$27,61075,081Indirect
Dec 4, 2023Common StockSSaleDisposed−1,482$20.08F6−$29,758.5653,020Indirect
Dec 4, 2023Common StockSSaleDisposed−1,483$20.08F6−$29,778.6453,042Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $20.000 to $20.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $20.010 to $20.395, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)